Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

On December 1, 2021 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported it has completed its share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group (Press release, Hoffmann-La Roche, DEC 1, 2021, View Source [SID1234596316]). TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will build on their capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With over 45 CE-IVD assays and more than a 100 research-use-only assays joining the Roche family, the companies will jointly accelerate access for patients around the world to even more clinically important diagnostic tests. TIB Molbiol will further expand Roche’s molecular diagnostics solutions, especially for the flexible open platforms LightCycler PCR and MagNA Pure sample preparation systems.

The two companies have collaborated for more than 20 years to rapidly address critical healthcare needs including biological threats, such as SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days.

"I am very pleased that together with TIB Molbiol, we can significantly improve access for patients to a broader spectrum of diagnostic tests – from high volume routine tests to the diagnosis of rare diseases. TIB Molbiol will continue to be an innovation engine and frontrunner in our common fight against infectious diseases, such as SARS-CoV-2", said Thomas Schinecker, CEO Roche Diagnostics. "TIB Molbiol has helped to shape the future of PCR infectious disease testing, and will continue to drive cutting-edge research so we can bring better healthcare outcomes to patients faster."

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

On December 1, 2021 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, reported that 15 of 30 participants have been recruited in the diagnostic 64Cu SAR-bisPSMA clinical trial (PROPELLER) in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy (Press release, Clarity Pharmaceuticals, DEC 1, 2021, View Source [SID1234596315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

68Ga PSMA-11 (~200MBq, left) vs. 64Cu SAR-bisPSMA (~200MBq, right) in the same patient; time between serial imaging was 8 days. Standardised Uptake Value (SUVmax)* of the lesions were 6.5 and 6.3 for 68Ga PSMA-11 and 16.5 and 18.5 for 64Cu SAR-bisPSMA

*SUV is a measurement of product uptake in tissue normalised to a distribution volume

Clarity’s Executive Chairman, Dr Alan Taylor, commented, "We are excited to have quickly and successfully recruited half of the patients planned for the PROPELLER trial with all three sites actively recruiting and imaging prostate cancer patients across Australia. We have been able to not only generate strong preliminary clinical data since the trial commencement in July 2021, but also validate our on-demand distribution model where the 64Cu-SAR-bisPSMA has been shipped to the trial sites across Australia from a central manufacturing facility with minimal delays or interruptions. The pace and quality of work that we were able to achieve during this trial is reflective of the appetite for the new generation of radiopharmaceuticals that can cater to large indications in the oncology space and shift the radiopharmaceutical field towards the "big pharma" model with central manufacture of ready-to-use products. This shift has potential to significantly improve patient care by focusing on the needs of patients and enable their treating staff to access critical treatments that are safe and efficacious, on time and at any treatment centre with a positron emission tomography (PET) camera."

The PROPELLER trial is a Phase I Positron Emission Tomography (PET) imaging trial of participants with confirmed prostate cancer using 64Cu SAR-bisPSMA. It is a 30-patient multi-centre, blinded review, dose ranging, non-randomised study of 64Cu-SAR-bisPSMA administered to patients with confirmed prostate cancer prior to radical prostatectomy (NCT04839367)1. The main goals of the PROPELLER trial are to:

Determine the safety and tolerability of 64Cu SAR-bisPSMA in participants with untreated, confirmed prostate cancer and planned for radical prostatectomy;
Examine 64Cu SAR-bisPSMA at different dose levels;
Determine the ability of 64Cu SAR-bisPSMA to detect primary prostate cancer; and
Compare diagnostic properties of 64Cu SAR-bisPSMA against 68Ga PSMA-11, the standard of care for prostate cancer imaging in Australia.
Prof Louise Emmett (St Vincent’s Hospital Sydney), Principal Investigator in the PROPELLER trial commented, "The preliminary data from the patients imaged in the PROPELLER trial to date looks very promising as it supports the evidence of higher uptake of 64Cu SAR-bisPSMA in the tumours that has been shown in the pre-clinical studies. Higher uptake in the tumours means that they are more visible on the PET scans and hence have a higher chance of being detected. These initial results are encouraging for further development of this product as a diagnostic, and the higher uptake and retention also make it an exciting therapeutic target with 67Cu. In addition to the anticipated clinical benefits, having access to centrally manufactured products has the potential to improve patient care by providing an alternative to currently used short-lived diagnostic radioisotopes, such as 68Ga and 18F, the production of which can pose challenges in delivering critical imaging scans to patients with cancer on time. I am very pleased to be working with Clarity on the Targeted Copper Theranostics (TCT) platform of products, having recently completed the C-BOBCAT trial of SAR-Bombesin, in hopes that these products will improve the current treatment paradigm for oncology patients."

Dr Alan Taylor further commented, "Clarity is well on track to explore and validate the benefits of the TCT platform, including the logistical, manufacturing and treatment benefits associated with the "perfect pairing" of copper-64 and copper-67. These benefits hold promise of providing a large patient population with early, accurate and precise detection of prostate cancer. As such, we look forward to recruiting the remaining 50% of patients and generating more data to validate the compelling results from our preclinical studies as well as the exciting preliminary results from the PROPELLER trial and our US-based 64/67Cu SAR-bisPSMA theranostic trial (SECuRE trial (NCT04868604)2) in pursuit of our ultimate goal of improving treatment outcomes for children and adults with cancer."

This announcement has been authorised for release by the Executive Chairman.

About Prostate Cancer
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide3. In 2021, the National Cancer Institute estimated 248,530 new cases of prostate cancer in the US and around 34,130 deaths from the disease4. Annually, there are around ~34,000 men in the US who are diagnosed with mCRCP5, ~90% of whom have tumours which express PSMA6.

EpiAxis to present at Emergence 2022

On December 1, 2021 EpiAxis Therapeutics reported that among the first batch of companies that will present at Wholesale Investor’s fifth annual Emergence 2022 event in March (Press release, EpiAxis Therapeutics, DEC 1, 2021, View Source;utm_medium=rss&utm_campaign=epiaxis-presents-emergence-2022 [SID1234596314]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It’s the first time the event has been held live in two years. The annual Emergence event brings together high-growth companies from fintech, renewable energy, biotech and ecommerce to showcase their investment opportunities. Companies included in the first announcement alongside EpiAxis include SelfWealth, Novapep, Long Pipes, EG Funds and Horizon 3 Biotech.

"We are delighted to be part of this group announcement with Wholesale Investor and look forward to presenting EpiAxis at the event, sharing our progress on the development of novel therapeutics for metastatic disease," said EpiAxis CEO Dr Jeremy Chrisp.

Wholesale Investor events have connected $187million of capital in just under four years, showcased to more than 29,000 high net-worth investors and investment groups at events spanning nine countries and 12 cities. EpiAxis became part of the investment platform in October. Our membership kicked off with Dr Chrisp presenting at Wholesale Investor’s STEM 2021 Conference. It was a valuable opportunity to network with investors interested in biotech and discuss how our epigenetic science aims to maintain and extend cancer remission, with low side effects

Emergence 2022 will be held from March 9-11, 2022. Click here to book tickets to the event.

GlyTherix awarded NSW Government TechVoucher to evaluate efficacy of our cancer antibody Miltuximab®

On December 1, 2021 GlyTherix reported the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams (Press release, Glytherix, DEC 1, 2021, View Source [SID1234596313]). Funds will be used to generate new preclinical models to evaluate the efficacy, biodistribution, and pharmacokinetics of our lead cancer immunotherapy antibody, Miltuximab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent installation of start-of-the-art PET-CT and SPECT-CT imaging systems at ANSTO will facilitate high-resolution small animal imaging of Miltuximab.

The theranostic products produced and tested in this project will generate significant input for the design of our Phase Ib trial to ensure that safety and efficacy endpoints will be met with confidence.

Dr Brad Walsh, CEO GlyTherix, commented "We are extremely grateful to the NSW Government for their continued support of our important therapeutic program, particularly as we have a first-in-world radio-immunotherapy developed in NSW. Additionally, we are pleased that this strengthens our long collaboration with ANSTO who have partnered with us in developing this radioimmunotherapy. A win-win for NSW companies."